AR066165A1 - Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae - Google Patents
Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridaeInfo
- Publication number
- AR066165A1 AR066165A1 ARP080104066A ARP080104066A AR066165A1 AR 066165 A1 AR066165 A1 AR 066165A1 AR P080104066 A ARP080104066 A AR P080104066A AR P080104066 A ARP080104066 A AR P080104066A AR 066165 A1 AR066165 A1 AR 066165A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- analogue
- clemizol
- methods
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title 3
- 230000009385 viral infection Effects 0.000 title 3
- 241000710781 Flaviviridae Species 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 11
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 abstract 6
- 241000711549 Hepacivirus C Species 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 abstract 3
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 abstract 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- NYKCGQQJNVPOLU-ONTIZHBOSA-N spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 abstract 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 101800001019 Non-structural protein 4B Proteins 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229960004621 cinoxacin Drugs 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 150000002871 norepinephrines Chemical class 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229950006495 spiradoline Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 229960004791 tropicamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97330907P | 2007-09-18 | 2007-09-18 | |
| US8875908P | 2008-08-14 | 2008-08-14 | |
| US9253708P | 2008-08-28 | 2008-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066165A1 true AR066165A1 (es) | 2009-07-29 |
Family
ID=40468758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104066A AR066165A1 (es) | 2007-09-18 | 2008-09-18 | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9061010B2 (enExample) |
| EP (1) | EP2203168B1 (enExample) |
| JP (1) | JP5715820B2 (enExample) |
| CN (1) | CN101903026B (enExample) |
| AR (1) | AR066165A1 (enExample) |
| AU (1) | AU2008302295B2 (enExample) |
| TW (1) | TW200927102A (enExample) |
| WO (2) | WO2009039248A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| US9149463B2 (en) | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| WO2009039248A2 (en) | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| EP2408448A4 (en) * | 2009-03-18 | 2012-09-19 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
| WO2010118286A2 (en) * | 2009-04-09 | 2010-10-14 | Auspex Pharmaceuticals, Inc. | Benzimidazole modulators of h1 receptor and/or ns4b protein activity |
| WO2010132810A1 (en) * | 2009-05-15 | 2010-11-18 | Concert Pharmaceuticals, Inc. | Deuterium modified benzimidazoles |
| RU2407738C1 (ru) * | 2009-07-03 | 2010-12-27 | Общество с ограниченной ответственностью "Интеллектуальный Диалог" | Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| CN102666537A (zh) * | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| JP6106603B2 (ja) * | 2011-01-11 | 2017-04-05 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| CA2831710A1 (en) | 2011-03-31 | 2012-10-04 | Bayer Intellectual Property Gmbh | Substituted benzimidazoles as mps-1 kinase inhibitors |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| MX349036B (es) | 2011-12-06 | 2017-07-07 | Univ Leland Stanford Junior | Metodos y composiciones para tratar enfermedades virales. |
| CA2874303C (en) * | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| CN103585616B (zh) * | 2013-08-14 | 2015-05-27 | 南京工业大学 | 二肽类似物的用途 |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| WO2015050998A2 (en) | 2013-10-01 | 2015-04-09 | The Broad Institute, Inc. | Sieve valves, microfluidic circuits, microfluidic devices, kits, and methods for isolating an analyte |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| CA3294570A1 (en) * | 2015-06-30 | 2026-03-02 | Eiger Group International, Inc. | Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation |
| EA201892200A1 (ru) * | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| SI3442580T1 (sl) | 2016-04-11 | 2021-01-29 | Genfit | Metode zdravljenja holestatičnih in fibrotičnih bolezni |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| WO2018129702A1 (zh) * | 2017-01-13 | 2018-07-19 | 史仅 | 蚊虫叮咬瘙痒寨卡等病毒预防医疗器具 |
| CN108096562B (zh) * | 2017-12-25 | 2021-05-11 | 武汉百药联科科技有限公司 | 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途 |
| WO2019126860A1 (pt) * | 2017-12-29 | 2019-07-04 | Instituto Butantan | Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição |
| CN108660253B (zh) * | 2018-04-17 | 2022-05-31 | 广东省妇幼保健院（广东省妇产医院、广东省儿童医院） | 一种基于悬浮微珠阵列系统检测虫媒介病毒的探针、引物、检测试剂盒及检测方法 |
| CN109020895B (zh) * | 2018-08-07 | 2020-04-24 | 枣庄学院 | 一种金属催化的1-苄胺基取代苯并咪唑的合成方法 |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| US20200323830A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with etoricoxib |
| EP4010481A4 (en) | 2019-08-09 | 2023-09-20 | Nutcracker Therapeutics, Inc. | MICROFLUIDIC DEVICE AND METHODS OF USE |
| WO2021180251A1 (zh) * | 2020-03-09 | 2021-09-16 | 北京强新生物科技有限公司 | 治疗冠状病毒感染的联用药物及治疗方法 |
| CN111393372B (zh) * | 2020-05-12 | 2022-08-26 | 中国药科大学 | 一种苯并咪唑衍生物及其制备方法和用途 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| US20250120951A1 (en) * | 2021-07-30 | 2025-04-17 | Epygenix Therapeutics, Inc. | Clemizole formulation |
| WO2023225324A1 (en) * | 2022-05-20 | 2023-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating fatty liver and viral infections |
| CN119707828B (zh) * | 2024-12-18 | 2025-12-05 | 江苏天和制药股份有限公司 | 一种盐酸克立咪唑的合成方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689853A (en) * | 1954-09-21 | Certain i | ||
| US2684327A (en) | 1951-11-02 | 1954-07-20 | United Chromium Inc | Bright nickel plating |
| GB1045534A (en) | 1963-02-09 | 1966-10-12 | Schering Ag | New 1-benzyl-5,6-dialkoxy benzimidazoles and a process for their manufacture |
| DE1620449C3 (de) | 1964-07-23 | 1974-02-21 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Substituierte Benzimidazole und Verfahren zu ihrer Herstellung |
| US3428634A (en) | 1965-03-13 | 1969-02-18 | Acraf | 3-tertiary amino alkoxy-1-hydrocarbon indazoles |
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4269835A (en) * | 1979-12-13 | 1981-05-26 | Whittle Barry J | Nasal composition for relieving nasal distress |
| PE27997A1 (es) | 1994-04-29 | 1997-09-20 | Lilly Co Eli | Antagonistas de receptores de taquicininas |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| EP0963371B1 (en) * | 1997-02-25 | 2003-05-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| US6770666B2 (en) * | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6476062B2 (en) | 2000-03-30 | 2002-11-05 | Schering Corporation | Chemokine receptor antagonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
| WO2002076451A1 (en) | 2001-03-22 | 2002-10-03 | Ucb, S.A. | Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| WO2003060475A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| TW200902047A (en) | 2003-02-14 | 2009-01-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| PT1611088E (pt) | 2003-04-07 | 2009-09-24 | Pharmacyclics Inc | Hidroxamatos como agentes terapêuticos |
| BRPI0413234A (pt) | 2003-08-01 | 2006-10-03 | Genelabs Tech Inc | derivados de imidazola bicìclica contra flaviviridae |
| US7582428B2 (en) * | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
| TW200522932A (en) | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20070269420A1 (en) * | 2003-11-24 | 2007-11-22 | Chunduru Srinivas K | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases |
| KR20060114022A (ko) | 2004-02-27 | 2006-11-03 | 에프. 호프만-라 로슈 아게 | 인다졸 유도체 및 그들을 함유하는 약학 조성물 |
| GB0416728D0 (en) | 2004-07-27 | 2004-09-01 | 7Tm Pharma As | Medicinal use of receptor ligands |
| CN101027303A (zh) | 2004-07-27 | 2007-08-29 | 吉里德科学公司 | 咪唑并[4，5－d]嘧啶类、其应用和制备方法 |
| WO2006135383A2 (en) | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| EP1888033B1 (en) | 2005-06-09 | 2014-02-19 | Meda AB | Method and composition for treating inflammatory disorders |
| EP1988776B1 (en) * | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| WO2007115077A2 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| WO2009039248A2 (en) | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
-
2008
- 2008-09-18 WO PCT/US2008/076806 patent/WO2009039248A2/en not_active Ceased
- 2008-09-18 EP EP08832123.7A patent/EP2203168B1/en not_active Not-in-force
- 2008-09-18 AR ARP080104066A patent/AR066165A1/es unknown
- 2008-09-18 US US12/677,989 patent/US9061010B2/en not_active Expired - Fee Related
- 2008-09-18 JP JP2010525943A patent/JP5715820B2/ja not_active Expired - Fee Related
- 2008-09-18 AU AU2008302295A patent/AU2008302295B2/en not_active Ceased
- 2008-09-18 TW TW097135844A patent/TW200927102A/zh unknown
- 2008-09-18 CN CN200880116387XA patent/CN101903026B/zh not_active Expired - Fee Related
- 2008-09-18 WO PCT/US2008/076804 patent/WO2009039246A2/en not_active Ceased
- 2008-09-18 US US12/678,014 patent/US8895598B2/en not_active Expired - Fee Related
-
2014
- 2014-09-23 US US14/493,529 patent/US20150044169A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110052536A1 (en) | 2011-03-03 |
| JP2010539241A (ja) | 2010-12-16 |
| US20150044169A1 (en) | 2015-02-12 |
| WO2009039248A2 (en) | 2009-03-26 |
| CN101903026B (zh) | 2013-05-08 |
| EP2203168B1 (en) | 2014-07-16 |
| EP2203168A4 (en) | 2011-10-26 |
| US9061010B2 (en) | 2015-06-23 |
| EP2203168A2 (en) | 2010-07-07 |
| AU2008302295A1 (en) | 2009-03-26 |
| JP5715820B2 (ja) | 2015-05-13 |
| WO2009039248A3 (en) | 2009-09-24 |
| WO2009039246A2 (en) | 2009-03-26 |
| US20100260717A1 (en) | 2010-10-14 |
| AU2008302295B2 (en) | 2013-11-28 |
| WO2009039248A8 (en) | 2009-05-28 |
| US8895598B2 (en) | 2014-11-25 |
| CN101903026A (zh) | 2010-12-01 |
| TW200927102A (en) | 2009-07-01 |
| WO2009039246A3 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2671478T3 (es) | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales | |
| JP2010539241A5 (enExample) | ||
| CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| RU2483073C2 (ru) | Фосфадиазиновые ингибиторы iv полимеразы hcv | |
| AR084393A1 (es) | Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc | |
| EA200700338A1 (ru) | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием | |
| BR0305259A (pt) | Inibidores de hcv ns5b polimerase | |
| ES2561888T3 (es) | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae | |
| UY28581A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| EA200802346A1 (ru) | Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с | |
| JP2014514308A5 (enExample) | ||
| BRPI0416902A (pt) | inibidores de ns3/ns4a serina protease do vìrus da hepatite c | |
| EA201000201A1 (ru) | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| JP2015525221A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| AR078976A1 (es) | Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc | |
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| ATE475660T1 (de) | Antivirale verbindungen | |
| JP2010508361A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| CU23787B7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
| JP2011523651A5 (enExample) | ||
| EA200701849A1 (ru) | Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |